Latham BioPharm Group, part of SIA Partners, today announced receiving a new Indefinite Delivery, Indefinite Quantity (IDIQ) contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), titled Preclinical Services for Biopharmaceuticals Product Development.
Read Press ReleaseComplimentary Workshop to Provide Expert Insight and Strategies for Regulatory Affairs Specialists, Pharmaceutical Enthusiasts and Drug Developers
Read Press ReleaseManuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function.
Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m. in San Diego entitled “Novel stem cell-derived islet-like clusters potently control rodent blood glycemia”.
Seraxis will be taking meetings at BIO-Europe, November 6-8, in Munich.
Former site of US Compounding is acquired by up-and-comer in custom compounded pharmaceuticals, FarmaKeio, as part of ongoing expansion to support availability and delivery of custom compounded medications nationwide.
Read Press ReleaseCommonsense Online and Mobile Approach to Identifying and Engaging With Drug Manufacturers to Meet DSCSA Requirements — Including Drop Shipment Transactions
Read Press ReleaseNew biologics outsourcing solution provider leverages proven track record of Tanvex BioPharma USA Inc. to help early-stage companies bring mammalian and microbial derived biologics from concept to commercialization.
Read Press ReleaseSenzo Health Limited (London, UK) ("Senzo"), a life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, this week announced an additional $1.8m investment for its breakthrough Amplified Lateral Flow (ALF) test technology, advancing its mission to bring high-quality, affordable tests into the home.
Read Press ReleaseThe leader in ADHD assessments will feature a series of podcasts and webinars covering ADHD resources, insights, discussions, destigmatization efforts for this condition, and the pursuit of optimal ADHD treatment.
Read Press ReleaseA recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and PARPi therapy, exploring the genomic and clinical features that may lead to different responses, and investigates the mechanisms of resistance.
Read Press ReleaseDr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis’ presentation, entitled “Stem-cell Derived Islets for Treating Diabetes”, will be delivered in the session entitled "Transplantation of Islet and Stem Cells Today and Tomorrow".
Read Press ReleaseFollowing the launch of its Marketplace in 2022, Hyris continues to leverage the AI capabilities of its genetic testing platform, renowned for its adaptability, to support both researchers and kit developers worldwide. New onboarding programs enable emerging players to accelerate their go-to-market, as well as established manufacturers and diagnostic providers to integrate their portfolio with ease, maximizing their cost-per-value strategy.
Read Press ReleaseLeadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date
Amelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment.
Read Press ReleaseBrainify.AI, an innovative company leveraging artificial intelligence to revolutionize the treatment of depression, is excited to announce it has joined Johnson & Johnson Innovation JLABS (JLABS) as a resident company. This marks a significant milestone for Brainify.AI and is another indication of the value and promise the company brings to the medical AI field.
Read Press Release